TCBP (TC BioPharm (Holdings)) Other Net Income (Loss) : $-0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Other Net Income (Loss)?

TC BioPharm (Holdings)'s Other Net Income (Loss) for the three months ended in Jun. 2024 was $-0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.00 Mil.

TC BioPharm (Holdings)'s quarterly Other Net Income (Loss) stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) but then declined from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil).

TC BioPharm (Holdings)'s annual Other Net Income (Loss) increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil) and increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).

TC BioPharm (Holdings) Other Net Income (Loss) Historical Data

The historical data trend for TC BioPharm (Holdings)'s Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Other Net Income (Loss) Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Other Net Income (Loss)	Get a 7-Day Free Trial								-	-	-	-	-

TC BioPharm (Holdings) Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

TC BioPharm (Holdings) Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD